一品红(300723.SZ)：子公司获得丙戊酸钠注射用浓溶液注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the drug registration certificate of sodium valproate injection solution, indicating a significant development in its product offerings [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for sodium valproate injection solution [1] - The approved indication for sodium valproate injection is for the treatment of epilepsy, particularly when oral formulations cannot be administered in adults and children [1] Group 2: Mechanism of Action - Sodium valproate exists in the blood as valproate ions, and its therapeutic mechanism is not fully understood [1] - The antiepileptic activity of sodium valproate may be related to the increase in the concentration of gamma-aminobutyric acid (GABA) in the brain [1]